Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
Date:10/14/2010

ATLANTA, Oct. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 third quarter financial results will be released on Thursday, November 4, 2010.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available November 4 through November 11 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The account number for the replay is 244 and the conference number is 359197.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada.  The Company's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  The Company's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  The Company's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  In late September, CryoLife entered into a distribution agreement for PerClot®, an absorbable powder hemostat that has CE Mark designation allowing commercial distribution into the European Community.  CryoLife currently distributes HemoStase®, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in many international markets for cardiac, vascular, and general surgery, subject to certain exclusions, although CryoLife has received notice from Medafor, Inc. that it has terminated its HemoStase distribution agreement with CryoLife.  

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com.Media Contact:D. Ashley LeeExecutive Vice President, Chief Financial Officer andChief Operating OfficerPhone: 770-419-3355
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... 03, 2020 , ... In response to the COVID-19 pandemic ... classrooms across the United States, IntraLogic Solutions , a leading national school ... a non-contact, wall-mounted scanning thermometer that rapidly checks body temperatures. When a level ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... will host the Agilent Science and Technology Virtual Symposium 2020 (ASTVS 2020) ... Agilent will open a suite of Live webinars and Networking sessions, with a ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are ... (CDC), About 3% of breast cancers (about 7,500 women per year) and 10% of ... and BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put ... and look for ways to trim the fat from our monthly expenses and put more ... it’s also important that you have a financial safety net in place in case something ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang ... persons with autism and other developmental disabilities, as well as supporting staff in ... adolescents with autism, school consultation, and staff development. She joined the company in ...
(Date:8/28/2020)... ... 28, 2020 , ... Ernst & Young LLP (EY US) ... Of The Year® 2020 Florida Award finalist. Now in its 34th year, the ... growth and prosperity as they build and sustain successful businesses that transform our ...
(Date:8/28/2020)... ... August 28, 2020 , ... With ... set out to continue helping the specialty-diet community connect with great, gluten-free brands. ... get coupons, enter giveaways, chat with brands & watch over 50 educational classes... ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... that strongly suggest that obese individuals are at an increased risk of developing ... more likely to catch COVID-19; however, because the same organ systems that the ...
Breaking Medicine News(10 mins):